Log In
BCIQ
Print this Print this
 

Agilect, Azilect, rasagiline

Also known as: mesylate

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionIrreversible selective inhibitor of monoamine oxidase B (MAO-B)
Molecular Target Monoamine oxidase B (MAO-B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsSlow clinical progression of Parkinson's disease (PD); Treat early Parkinson's disease (PD); Treat early, moderate and advanced stage Parkinson's disease (PD); Treat mild cognitive impairment (MCI) in Parkinson's disease (PD); Treat moderate to advanced Parkinson's disease (PD) in patients who experience motor fluctuations; Treat Parkinson's disease (PD)
Regulatory Designation
PartnerH. Lundbeck A/S;
Takeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/05/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today